MicroMass recruits three strategy vets

Share this article:
MicroMass Communications has added three new VP, senior strategists to better address the marketing shift from mass-market communications to a more patient-focused approach.

Account planning veteran Mark Klapper joins the Cary, NC-based relationship marketing agency from Unit 7, where he led planners, analysts and psychologists as EVP, director of planning and consulting services.

Kim Levy, a 17-year pharma marketing veteran of both the corporate and agency sides, joins MicroMass to develop strategy on the agency's oncology accounts. Prior to joining MicroMass, Levy was at Adair-Greene Healthcare Communications.

Rick Mazzetti joins MicroMass with over 20 years of pharma industry experience including marketing, sales management and alliance management positions at GlaxoSmithKline, Quintiles Transnational, and LipoScience. His previous brand management experience lies in the areas of central nervous system, cardiology, women's health, men's health, dermatology, and antibiotics.
President Jay Bigelow said in a statement that these new hires come as the agency addresses the ongoing industry shift away from investing in direct-to-consumer advertising.

“With increased pressure to cut back on direct-to-consumer advertising, we are finding that more and more brands are looking for alternate strategies to communicate with patients and professionals, such as relationship marketing and disease awareness campaigns,” Bigelow said. “Enhanced by these new hires, our strategic services group… [will] help clients navigate through this change.”

Share this article:

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...